Short and Lockwood (1995) [[10]] | Choi et al. (2000) [[1]] | Yokogawa and Vivino (2009) [[9]] | |
---|---|---|---|
Number of patients | 10 | 10 | 68 |
Age range (years) | 55–76 | 45–81 | 60–67 |
Females (%), female/total patients | 70 (7/10) | 70 (7/10) | 59 (40/68) |
Hydralazine dose range (mg/day) | 50–150 | 75–200 | 50–300 |
Duration of drug exposure (months) | 36–156 | 12–63 | 0.73 to >120 |
Patients with renal involvement | 10 | 9 | 55 |
Patients with cutaneous involvement | 4 | 3 | 25 |
Patients with pulmonary involvement | 2 | 5 | 13 |
Confirmed pauci-immune GN | 7 | 5 | >25 * |
ANCA-positive | 10 | 10 | 45 |
MPO-positive | 10 | 10 | 45 |
Anti-histone-positive (patients) | NR | NR | (12/12) |